Novavax Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Novavax Stock Forecast and Price Target
Given the average yearlong price target of $11.00 provided by four prominent analysts over the past few months, there is a potential upside of approximately 123.12% from the last closing price in May, 2024 for Novavax's stock if it is reached. This estimation is based on a high estimate of $38.00 and a low estimate of $4.00. Even if you are not interested in NVAX stock, you should be aware of its competitors and their current standings.
123.12% Upside
Novavax Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Novavax's Price has grown, increasing from $0.00 to $0.00 – an increase of 100.00%. For next year, the 4 analysts predict Fair Value of $5.29, which would mean an increase of 100.00%. Over the next eight years, the pros' prediction is Fair Valueof $11.12, which would mean a eight-year growth forecast of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.27 | Buy/Sell | $174.55 | 13.89% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$127.51 | Buy/Sell | $130.51 | 12.15% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.50 | Buy/Sell | £165.99 | 35.23% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$27.81 | Buy/Sell | $32.87 | 9.67% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£17.34 | Buy/Sell | £17.30 | 12.46% |
Novavax Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Novavax's Revenue has grown, increasing from $475.60M to $983.71M – an increase of 106.84%. For next year, the 6 analysts predict Revenue of $1.27B, which would mean an increase of 29.12%. Over the next nine years, the pros' prediction is Revenueof $1.77B, which would mean a nine-year growth forecast of 80.21%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MRNA Stock Forecast | Moderna | Outperform |
16
|
$125.00 | Buy/Sell | $135.42 | 1.43% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.13k | Buy/Sell | ¥4.74k | 10.30% |
| BNTX Stock Forecast | BioNTech | Outperform |
12
|
$92.72 | Buy/Sell | $123.75 | 8.58% |
.jpg)
Novavax EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Novavax's EBITDA has grown by 28.39%, from $-409.13M to $-525.29M. For the following year, the 1 analysts predict that Novavax's EBITDA will drop by 46.88%, reaching $-279.03M. In 2030, the professionals' prediction is that NVAX's EBITDA will decrease by 55.06%, reaching $-236.05M.
Novavax EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Novavax's EBIT has grown from $-414.02M to $-566.51M – a 36.83% increase. In the following year, the 4 analysts surveyed believe that Novavax's EBIT will decrease by 120.22%, reaching $114.57M. According to professionals, by 2030, Novavax's EBIT will have decreased by 171.93%, falling down to $407.50M.
Novavax EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Novavax's EPS has grown, increasing from $-7.27 to $0.00 – an increase of 100.00%. For next year, the 4 analysts predict EPS of $-0.31, which would mean an increase of 100.00%. Over the next eight years, the pros' prediction is EPSof $1.73, which would mean a eight-year growth forecast of 100.00%.
.jpg)